U.S., Sept. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07178431) titled 'MB-CART2019.1 in Refractory Multiple Sclerosis' on July 28.
Brief Summary: The goal of this trial is to assess the feasibility, safety and preliminary efficacy of MB-CART2019.1 in patients with active refractory primary and secondary progressive MS.
Study Start Date: Oct. 30
Study Type: INTERVENTIONAL
Condition:
Multiple Sclerosis
CAR T Cell Therapy
Intervention:
BIOLOGICAL: MB-CART2019.1
CAR T cell therapy
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Miltenyi Biomedicine GmbH
Published by HT Digital Content Services with permission from Health Daily Digest....